CSPC Pharma Limited announced that its wholly-owned subsidiary, Shanghai Jintant Biotech Co., Ltd., signed an exclusive licensing agreement with Jiangsu Koning Jerry Biopharmaceutical Co., Ltd. on September 29, 2024, obtaining the rights to develop, sell, and commercialize the HER2 bispecific antibody drug JSKN003 in Mainland China. The drug is mainly used for the treatment of tumor-related indications. Jintant Biotech will pay Jiangsu Koning Jerry up to a maximum of RMB 1.23 billion in development and regulatory milestone payments, as well as up to a maximum of RMB 1.85 billion in potential sales milestone payments and double-digit percentage sales royalties. JSKN003 is currently undergoing Phase I clinical trials in Australia and Phase I/II and Phase III clinical trials in China.

CSPC Pharma Limited announced that its wholly-owned subsidiary, Shanghai Jintant Biotech Co., Ltd., signed an exclusive licensing agreement with Jiangsu Koning Jerry Biopharmaceutical Co., Ltd. on September 29, 2024, obtaining the rights to develop, sell, and commercialize the HER2 bispecific antibody drug JSKN003 in Mainland China. The drug is mainly used for the treatment of tumor-related indications. Jintant Biotech will pay Jiangsu Koning Jerry up to a maximum of RMB 1.23 billion in development and regulatory milestone payments, as well as up to a maximum of RMB 1.85 billion in potential sales milestone payments and double-digit percentage sales royalties. JSKN003 is currently undergoing Phase I clinical trials in Australia and Phase I/II and Phase III clinical trials in China.